북미의 T세포치료 시장 예측(-2030년) : 지역별 분석 - 모달리티별, 치료 유형별, 적응증별

The North America T cell therapy market was valued at US$ 1,645.52 million in 2022 and is expected to reach US$ 5,329.75 million by 2030; it is estimated to grow at a CAGR of 15.8% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Fuels the North America T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of cell therapy. Globally, cell therapies are widely adopted owing to the availability FDA approved products. Following is the list of T-cell therapy products approved by FDA in recent years:

For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).

In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the North America T cell therapy market growth.

North America T Cell Therapy Market Overview

The T-cell therapy market in North America is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players. Also, with an increase in clinical studies in CAR T-cell therapies, the market in North America is expected to grow during the forecast period. According to CDC, 1,603,844 new cancer cases were reported and 602,347 people died in the US in 2020. An estimated 184,720 people in the US will be diagnosed with leukemia, lymphoma, or myeloma in 2023.

Tisagenlecleucel (KymriahTM, Novartis, Morris Plains, NJ, US) and axicabtagene ciloleucel (YescartaTM, Gilead Sciences Canada, El Segundo, CA, US) were the first two CAR T-cells commercially available and approved in Canada by Health Canada in 2018 and 2019, respectively. Both are second-generation anti-CD19 CAR T-cells, approved for adult patients with r/r DLBCL, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. Moreover, Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) is the first to introduce CAR T-cell therapy in Canada. It uses a different kind of cell manufacturing that unveils less expensive and more equitable treatment. The Queen Elizabeth II Health Sciences Centre in Halifax became the first facility in Atlantic Canada to offer CAR T-cell therapy locally as of March 2022. Prior to this, Nova Scotia patients who were recommended for this highly personalized cancer medicine had to travel outside the country to receive the treatment. The program was made possible with a government investment of US$ 6.7 million annually. Thus, the rising cancer cases and initiative by the government fuel the T-cell therapy market in North America.

North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

North America T Cell Therapy Market Segmentation

The North America T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the North America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the North America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the North America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the North America T cell therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America T cell therapy market share in 2022.

Bluebird Bio Inc, Bristol-Myers Squibb Co, Cartesian Therapeutics Inc, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the North America T cell therapy market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 North America T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. North America T Cell Therapy Market - Key Industry Dynamics

• 4.1 Market Drivers:
  • 4.1.1 Growing Burden of Cancer Worldwide
  • 4.1.2 Increasing Number of T-Cell Therapy Approvals
• 4.2 Market Restraints
  • 4.2.1 Side-effects of CAR T-Cell Therapy
• 4.3 Market Opportunities
  • 4.3.1 Growing Investment in T-Cell Therapy
• 4.4 Future Trends
  • 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
• 4.5 Impact Analysis:

5. T Cell Therapy Market - North America Market Analysis

• 5.1 North America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

• 6.1 Overview
• 6.2 North America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
• 6.3 Research
  • 6.3.1 Overview
  • 6.3.2 Research: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Commercialized
  • 6.4.1 Overview
  • 6.4.2 Commercialized: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

• 7.1 Overview
• 7.2 North America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
• 7.3 CAR T-cell Therapy
  • 7.3.1 Overview
  • 7.3.2 CAR T-cell Therapy: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 T-cell Receptor (TCR)-based.
  • 7.4.1 Overview
  • 7.4.2 T-cell Receptor (TCR)-based: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication.

• 8.1 Overview
• 8.2 North America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
• 8.3 Hematologic Malignancies
  • 8.3.1 Overview
  • 8.3.2 Hematologic Malignancies: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3.3 North America T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
• 8.4 Solid Tumor
  • 8.4.1 Overview
  • 8.4.2 Solid Tumor: North America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America T Cell Therapy Market - Country Analysis

• 9.1 Overview
  • 9.1.1.1 North America T Cell Therapy Market, by Country
  • 9.1.1.2 US
    • 9.1.1.2.1 US: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 9.1.1.2.2 US: North America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 9.1.1.2.3 US: North America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 9.1.1.2.4 US: North America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 9.1.1.2.4.1 US: North America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 9.1.1.3 Canada
    • 9.1.1.3.1 Canada: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 9.1.1.3.2 Canada: North America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 9.1.1.3.3 Canada: North America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 9.1.1.3.4 Canada: North America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 9.1.1.3.4.1 Canada: North America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
  • 9.1.1.4 Mexico
    • 9.1.1.4.1 Mexico: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    • 9.1.1.4.2 Mexico: North America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
    • 9.1.1.4.3 Mexico: North America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    • 9.1.1.4.4 Mexico: North America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
    • 9.1.1.4.4.1 Mexico: North America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

10. T Cell Therapy Market-Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in T Cell Therapy Market
• 10.3 Organic Growth Strategies
  • 10.3.1 Overview
• 10.4 Inorganic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Legend Biotech Corp
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Janssen Global Services LLC
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Gilead Sciences Inc
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Bristol-Myers Squibb Co
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Novartis AG
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Cartesian Therapeutics Inc
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 Innovent Biologics Inc
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms